Michele Basso - Concepedia

Author

Michele Basso

Università Cattolica del Sacro Cuore ORCID

Also Known As

Basso Michele, M Basso, M. Basso, MICHELE BASSO, Massimo Siciliano, Michele Basso

100

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Università Cattolica del Sacro Cuore Agostino Gemelli University Polyclinic Istituti di Ricovero e Cura a Carattere Scientifico Centro di Riferimento Oncologico della Basilicata Fondazione IRCCS Istituto Nazionale dei Tumori

About

Michele Basso is an author at Università Cattolica del Sacro Cuore specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	266
2	Health Sciences	2	2	46
3	Gastroenterology	2	2	49
4	Hepatology	2	2	71
5	Cell Biology	1	1	74

Michele Basso

Publications

788

Citations

H-Index

Page 1

	Year	Citations
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib Massimo Iavarone, Giuseppe Cabibbo, Marco Biolato, Hepatology	2015	130
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases Carlo Barone, Alessandra Cassano, Michele Basso, British Journal of Cancer	2007	125
c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors Antonia Strippoli, Alessandra Cocomazzi, Michele Basso, Cancers C-myc ExpressionColorectal Cancer ResistancePathologyCancer BiologyTumor Biology	2020	74
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation Maria Alessandra Calegari, Alessandro Inno, Santa Monterisi, British Journal of Cancer	2017	57
Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study Roberto Iezzi, Valentina Angela Marsico, Alessandra Guerra, CardioVascular and Interventional Radiology OncologyHepatologyMedicineIrinotecan-loaded Drug-eluting BeadsPharmacotherapy	2015	48
Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer Donatella Lucchetti, Ina Valeria Zurlo, Filomena Colella, Scientific Reports	2021	37
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse Armando Orlandi, Maria Alessandra Calegari, Maurizio Martini, Clinical & Translational Oncology Pancreatic CancerGastrointestinal OncologyMedicineGemcitabine Versus FolfirinoxGastroenterology	2016	35
IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in <i>RAS</i> mutant metastatic colorectal cancer patients Mariantonietta Di Salvatore, Filippo Pietrantonio, Armando Orlandi, Oncotarget	2017	32
Novel Epigenetic Eight-Gene Signature Predictive of Poor Prognosis and MSI-Like Phenotype in Human Metastatic Colorectal Carcinomas Valentina Condelli, Giovanni Calice, Alessandra Cassano, Cancers Msi-like PhenotypeMethylation EventsHealth SciencesMedicineEpigenetic Change	2021	32
KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients Michele Basso, Antonia Strippoli, Armando Orlandi, British Journal of Cancer	2012	28

Page 1